CVC Capital Proposes €10.9 Billion Takeover of Italian Pharma Recordati
核心洞察
CVC Capital Partners (搜索) has offered €52 per share to acquire the remaining 48.2% of Recordati shares, valuing the deal at €10.9 billion.
The acquisition would give CVC full control of the Italian pharmaceutical company, which already holds a 51.8% controlling stake acquired in 2018.
Recordati's strong financial performance in 2025 included 11.8% revenue growth to €2.6 billion, driven primarily by a 29.7% increase in rare disease drug sales.
Italian pharmaceutical company Recordati is evaluating a €10.9 billion acquisition offer from private equity firm CVC Capital Partners (搜索), which seeks to acquire full ownership of the specialty drugmaker. CVC has proposed paying €52 per share for the remaining 48.2% of Recordati shares traded on the Italian Stock Exchange, building on its existing 51.8% controlling stake acquired in 2018 for €3.03 billion.
The century-old pharmaceutical company, which celebrates its 100th anniversary this year, has confirmed it is considering the offer but noted it has "not yet reviewed the indication of interest within its corporate bodies." Recordati operates as a global pharmaceutical group focused on primary and secondary care, with particular strength in rare diseases spanning hematological oncology, endocrinology, and metabolic health.
Strong Financial Performance Drives Valuation
Recordati's financial trajectory supports CVC's substantial valuation, with the company reporting net revenue growth of 11.8% to €2.6 billion in 2025. The performance was primarily driven by exceptional growth in rare disease therapeutics, where revenues surged 29.7% compared to 2024. This growth trajectory reflects the company's strategic focus on high-margin specialty drugs that command premium pricing due to limited competition and significant unmet medical needs.
The company's portfolio includes several key revenue drivers, most notably Isturisa (osilodrostat) for Cushing's disease (搜索), which GlobalData analysts project will generate $967 million in sales by 2031. Recordati recently expanded its rare disease portfolio by acquiring global rights to Enjaymo (sutimlimab), a cold agglutinin disease (搜索) treatment, from Sanofi for $825 million upfront in 2024.
Pipeline Development and Strategic Partnerships
Beyond its marketed products, Recordati has established strategic partnerships to advance its pipeline. The company is collaborating with mRNA specialist Moderna to develop mRNA-3927, a propionic acidemia (搜索) therapy currently in global Phase I/II trials. Additionally, the company's pipeline centers on cardiology and endocrinology, with istaroxime advancing in clinical studies as a novel agent for acute heart failure (搜索).
Recordati's established products continue to generate steady revenue streams, including Zanidip for hypertension (搜索) and Permixon (搜索) for urology applications. The company's strategy emphasizes bolt-on acquisitions to strengthen its pipeline while maintaining lower research and development burn rates compared to pure biotechnology companies.
M&A Activity Surge in Pharmaceutical Sector
CVC's proposed takeover occurs during a period of heightened pharmaceutical merger and acquisition activity, as companies seek to fortify their pipelines ahead of looming patent expiries. Recent major deals include Novartis's acquisition of Excellergy (搜索) for up to $3 billion, MSD's $6.7 billion purchase of Terns Pharmaceuticals, and Gilead's $2.2 billion acquisition of Ouro Medicines (搜索).
According to GlobalData analysis, the uptick in pharmaceutical deal value observed in 2025 signals renewed optimism for M&A activity, though acquirers are becoming more selective by concentrating investments into fewer high-value transactions. This trend reflects companies' strategic focus on acquiring assets with significant commercial potential and strong pipeline prospects.
The proposed Recordati acquisition would represent one of the largest pharmaceutical deals in the current M&A cycle, underscoring CVC's confidence in the company's rare disease portfolio and growth trajectory. For Recordati, the transaction would provide additional resources to advance its pipeline while maintaining its focus on specialty therapeutics and rare disease treatments.